References
- Beeksma FA, Erwich JJ, Khong TY. Placental fetal vascular thrombosis lesions and maternal thrombophilia. Pathology. 2012;44(1):24–28.
- Prüller F, Weiss EC, Raggam RB, et al. Activated protein C resistance assay and factor V Leiden. N Engl J Med. 2014;371(7):685–686.
- de Vries JI, van Pampus MG, Hague WM, et al. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. J Thromb Haemost. 2012;10(1):64–72.
- Kamimoto Y, Wada H, Ikejiri M, et al. Hypofibrinogenemia and the α-fibrinogen Thr312Ala polymorphism may be risk factors for early pregnancy loss. Clin Appl Thromb Hemost. 2017;23(1):52–57.
- Carter AM, Catto AJ, Grant PJ. Association of the alpha-fibrinogen Thr312Ala polymorphism with poststroke mortality in subjects with atrial fibrillation. Circulation. 1999;99(18):2423–2426.
- Roberge S, Nicolaides K, Demers S, et al. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. Am J Obstet Gynecol. 2017;216(2):110–120.e6.
- Isik H, Alptekin H, Selimoglu R, et al. Anticoagulant therapy in primary and second recurrent pregnancy losses with hereditary thrombophilia and perinatal outcomes. J Clin Exp Invest. 2016;7:29–34.
- Deligiannidis A, Parapanissiou E, Mavridis P, et al. Thrombophilia and antithrombotic therapy in women with recurrent spontaneous abortions. J Reprod Med. 2007;52(6):499–502.
- Leduc L, Dubois E, Takser L, et al. Dalteparin and low-dose aspirin in the prevention of adverse obstetric outcomes in women with inherited thrombophilia. J Obstet Gynaecol Can. 2007;29(10):787–793.
- Gris JC, Mercier E, Quéré I, et al. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood. 2004;103(10):3695–3699.
- Aracic N, Roje D, Jakus IA, et al. The impact of inherited thrombophilia types and low molecular weight heparin treatment on pregnancy complications in women with previous adverse outcome. Yonsei Med J. 2016;57(5):1230–1235.
- Grandone E, Brancaccio V, Colaizzo D, et al. Preventing adverse obstetric outcomes in women with genetic thrombophilia. Fertil Steril. 2002;78(2):371–375.
- Mitić G, Novakov Mikić A, Povazan L, et al. Thromboprophylaxis implementation during pregnancy in women with recurrent foetal losses and thrombophilia. Med Pregl. 2011;64(9–10):471–475.
- Monien S, Kadecki O, Baumgarten S, et al. Use of heparin in women with early and late miscarriages with and without thrombophilia. Clin Appl Thromb Hemost. 2009;15(6):636–644.
- Visser J, Ulander VM, Helmerhorst FM, et al. Thromboprophylaxis for recurrent miscarriage in women with or without thrombophilia. HABENOX: a randomised multicentre trial. Thromb Haemost. 2011;105(2):295–301.
- Kaandorp SP, Goddijn M, van der Post JAM, et al. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med. 2010;362(17):1586–1596.
- Ikejiri M, Wada H, Kamimoto Y, et al. Protection from pregnancy loss in women with hereditary thrombophilia when associated with fibrinogen polymorphism Thr331Ala. Clin Appl Thromb Hemost. 2017;23(5):494–495.
- Muszbek L, Bagoly Z, Bereczky Z, et al. The involvement of blood coagulation Factor XIII in fibrinolysis and thrombosis. Cardiovasc Hematol Agents Med Chem. 2008;6(3):190–205.
- Katzman PJ, Genest DR. Maternal floor infarction and massive perivillous fibrin deposition: histological definitions, association with intrauterine fetal growth restriction, and risk of recurrence. Pediatr Dev Pathol. 2002;5(2):159–164.
- Al-Sahan N, Grynspan D, von Dadelszen P, et al. Maternal floor infarction: management of an underrecognized pathology. J Obstet Gynaecol Res. 2014;40(1):293–296.
- Slone D, Siskind V, Heinonen OP, et al. Aspirin and congenital malformations. Lancet. 1976;1(7974):1373–1375.
- Rotchell YE, Cruickshank JK, Gay MP, et al. Barbados Low Dose Aspirin Study in Pregnancy (BLASP): a randomised trial for the prevention of pre-eclampsia and its complications. Br J Obstet Gynaecol. 1998;105(3):286–292.
- Di Sessa TG, Moretti ML, Khoury A, et al. Cardiac function in fetuses and newborns exposed to low-dose aspirin during pregnancy. Am J Obstet Gynecol. 1994;171(4):892–900.